Your browser doesn't support javascript.
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
Medigeshi, Guruprasad R; Batra, Gaurav; Murugesan, Deepika Rathna; Thiruvengadam, Ramachandran; Chattopadhyay, Souvick; Das, Bhabatosh; Gosain, Mudita; Singh, Janmejay; Anbalagan, Anantharaj; Shaman, Heena; Pargai, Kamal; Mehdi, Farha; Das, Soon Jyoti; Kahlon, Namrata; Singh, Savita; Kshetrapal, Pallavi; Wadhwa, Nitya; Pandey, Anil K; Bhatnagar, Shinjini; Garg, Pramod Kumar.
  • Medigeshi GR; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Batra G; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Murugesan DR; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Thiruvengadam R; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Chattopadhyay S; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Das B; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Gosain M; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Ayushi; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Singh J; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Anbalagan A; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Shaman H; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Pargai K; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Mehdi F; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Das SJ; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Kahlon N; ESIC Medical College and Hospital, Faridabad, Haryana, India.
  • Singh S; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Kshetrapal P; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Wadhwa N; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Pandey AK; ESIC Medical College and Hospital, Faridabad, Haryana, India.
  • Bhatnagar S; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India.
  • Garg PK; Translational Health Science and Technology Institute, Faridabad, Haryana 120001, India. Electronic address: pgarg@thsti.res.in.
EBioMedicine ; 78: 103938, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1739674
ABSTRACT

BACKGROUND:

Rapid spread of the omicron SARS-CoV-2 variant despite extensive vaccination suggests immune escape. The neutralising ability of different vaccines alone or with natural SARS-CoV-2 infection against omicron is not well-known.

METHODS:

In this cross-sectional study, we tested the ability of vaccine and natural infection induced antibodies to neutralise omicron variant in a live virus neutralisation assay in four groups of individuals (i) ChAdOx1 nCoV-19 vaccination, (ii) ChAdOx1 nCoV-19 vaccination plus prior SARS-CoV-2 infection, (iii) vaccination with inactivated virus vaccine (BBV152), and (iv) BBV152 vaccination plus prior SARS-CoV-2 infection. Primary outcome was fold-change in virus neutralisation titre against omicron compared with ancestral virus.

FINDINGS:

We included 80 subjects. The geometric mean titre (GMT) of the 50% focus reduction neutralisation test (FRNT50) was 380·4 (95% CI 221·1, 654·7) against the ancestral virus with BBV152 vaccination and 379·3 (95% CI 185·6, 775·2) with ChAdOx1 nCov-19 vaccination alone. GMT for vaccination plus infection groups were 806·1 (95% CI 478·5, 1357·8) and 1526·2 (95% CI 853·2, 2730·0), respectively. Against omicron variant, only 5 out of 20 in both BBV152 and ChAdOx1 nCoV-19 vaccine only groups, 6 out of 20 in BBV152 plus prior SARS-CoV-2 infection group, and 9 out of 20 in ChAdOx1 nCoV-19 plus prior SARS-CoV-2 infection group exhibited neutralisation titres above the lower limit of quantification (120) suggesting better neutralisation with prior infection. A reduction of 26·6 and 25·7 fold in FRNT50 titres against Omicron compared to ancestral SARS-CoV-2 strain was observed for individuals without prior SARS-CoV-2 infection vaccinated with BBV152 and ChAdOx1 nCoV-19, respectively. The corresponding reduction was 57·1 and 58·1 fold, respectively, for vaccinated individuals with prior infection. The 50% neutralisation titre against omicron demonstrated moderate correlation with serum anti-RBD IgG levels [Spearman r 0·58 (0·41, 0·71)].

INTERPRETATION:

Significant reduction in the neutralising ability of both vaccine-induced and vaccine plus infection-induced antibodies was observed for omicron variant which might explain immune escape.

FUNDING:

Department of Biotechnology, India; Bill & Melinda Gates Foundation, USA.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: EBioMedicine Year: 2022 Document Type: Article Affiliation country: J.ebiom.2022.103938

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: EBioMedicine Year: 2022 Document Type: Article Affiliation country: J.ebiom.2022.103938